What the studies show
Approval-grade reductions in HbA1c across the AWARD trials against placebo and active comparators; the licensed indication.
Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.
- 1Dulaglutide (Trulicity) product information and the AWARD clinical programme.FDA / EMA product informationLicensed indications and the glucose and weight data behind them.
In context
Dulaglutide is a once-weekly GLP-1 receptor agonist made of two GLP-1 analogue chains fused to an antibody fragment, approved for type 2 diabetes since 2014. In the 9,901-person REWIND trial it reduced major cardiovascular events by 12% relative to placebo over 5.4 years in people with diabetes, most of whom had no prior heart disease. It is not approved for weight management and produces modest weight loss — a few kilograms — well below semaglutide or tirzepatide. It is prescription-only everywhere it is sold.
Dulaglutide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Dulaglutide proven to help with blood glucose?
What studies are behind the grade?
Is Dulaglutide approved for this?
Other outcomes for Dulaglutide
- AMajor cardiovascular events (type 2 diabetes)1 large RCT (n=9,901, median 5.4 yr)
- ABody weightAWARD programme
- AAll-cause mortalityREWIND
- AGastrointestinal adverse effectsadverseREWIND
Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →